arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Mineralys Therapeutics, Inc.

MLYS

$15.25 ▼ -1.75 (-10.29%) at close

5 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Bearish

auto_awesome

Analytical Summary

Mineralys Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.0B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -20.8% ↗

FCF / Share $-2.10 ↗

Trailing P/E —

Price / Book 1.9x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

5-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-154.65M

↑ +13.0% —

FCF / Share Free cash flow per share

$-2.10

↑ +38.6% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
EPS Growth YoY (%)	37.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-83.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	65.5% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	13.0% Fair ↑ Fair Improving Year-over-year change in net income	-147.3% Weak Weak Year-over-year change in net income	-141.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	38.6% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-52.8% Weak Weak Year-over-year change in free cash flow	60.3% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
FCF / Net Income (x)	0.92x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.13x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Return on Invested Capital (%)	-20.8% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-79.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-27.7% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	47.6% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-25.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-93.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-33.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-27.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-23.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-259%)	-93.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-720%)	-29.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-299%)	57.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+280%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Net Debt (USD)	$-172.92M	$-114.09M	$-49.30M	$-87.70M	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Basic EPS, GAAP (USD)	$-2.29	$-3.66	$-1.99	$-5.77	—
Free Cash Flow per Share (USD)	$-2.10	$-3.43	$-2.24	$-5.65	—
Book Value per Share (USD)	$7.93	$3.84	$5.86	$-8.14	—
Tangible Book Value per Share (USD)	$7.93	$3.84	$5.86	$-8.14	—
Basic Weighted Avg Shares (shares)	67.66M	48.54M	36.19M	5.17M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Working Capital (USD)	$646.27M	$190.71M	$238.62M	$104.74M	—
Total Equity (USD)	$646.69M	$191.26M	$241.15M	$-52.27M	$-22.93M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Depreciation Expense (USD)	$59.00K	$43.00K	$0.00	—	—
Net Income, GAAP (USD)	$-154.65M	$-177.81M	$-71.90M	$-29.80M	—
Operating Cash Flow (USD)	$-142.42M	$-166.31M	$-81.17M	$-29.22M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 5 years · 19 quarters

Mineralys Therapeutics, Inc.

Analytical Summary

5-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare MLYS with peers